Key facts
- SR One Capital Management is a other based in Redwood City, California with 25 tracked portfolio companies.
- Notable positions include Kartos Therapeutics, Odyssey Therapeutics, VeraDermics (NYS: MANE), Avenzo Therapeutics, CORXEL Pharmaceuticals.
- SR One Capital Management has 20 funds on record, raising $1.5B across the 6 that report a size.
- SR One Capital Management reports $769.4M in regulatory assets under management across 19 private funds, per its SEC Form ADV (2026-03).
About SR One Capital Management
SR One Capital Management is a direct investment firm based in Redwood City, California. Established in 1985, the firm invests globally in emerging life science companies that are pursuing innovative science that will significantly impact medical care. SR One invests globally in early-stage healthcare companies pursuing innovative, breakthrough science. The assets of the firm are managed by the executive management team.
Registered with the SEC
Form ADV · 2026-03 · CRD 306361- Regulatory AUM
- $769.4M
- Private fund assets
- $2.4B
- Private funds
- 19 · 19 private equity
- Staff
- 28
- Registered office
- REDWOOD CITY, CA
- SEC status
- Approved
Reports custody of client assets.
Source: SEC Investment Adviser Public Disclosure, Form ADV (registered as SR ONE CAPITAL MANAGEMENT, LP).
Free account
See the whole book
- ·The book's top 25 — of 25 recorded positions
- ·Watchlist + alerts for SR One Capital Management's activity
Create free account
No card required
Portfolio, priced
25 companies · by our current valuations| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| Kartos Therapeutics | — | $650.0M | — | |
| Odyssey Therapeutics | Biotechnology | $638.2M | — | |
| VeraDermics (NYS: MANE) | Drug Discovery | $596.3M | — | |
| Avenzo Therapeutics | — | $590.0M | — | |
| CORXEL Pharmaceuticals | Drug Discovery | $474.9M | — | |
| Pulmocide | — | $291.6M | — | |
| Crystalys Therapeutics | — | $263.0M | — | |
| Korsana Biosciences | — | $243.5M | — | |
| Fore Biotherapeutics | — | $198.2M | — | |
| Avalyn Pharma | — | $155.0M | — | |
| Akamis Bio | — | $145.3M | — | |
| Topo Therapeutics | — | $137.6M | — | |
| Mission Therapeutics | — | $115.2M | — | |
| Draig Therapeutics | — | $44.0M | — | |
| Addition Therapeutics | — | $26.0M | — | |
| + 10 more companies · a free account shows the top of the book | ||||
Funds
6 of 20 recorded- SR One Co-Invest XIII, LLC2025—
- SR One Capital Fund III, LP2024$247.3M
- SR One Capital Opportunities Fund I, LP2023—
- SR One Co-Invest XI, LLC2022—
- SR One Co-Invest IX, LLC2022—
- SR One Co-Invest VIII, LLC2022—
$1.5B raised across the 6 funds that report a size
All 20 funds →Frequently asked
- What companies does SR One Capital Management invest in?
- SR One Capital Management has 25 recorded portfolio companies, including Kartos Therapeutics, Odyssey Therapeutics, VeraDermics (NYS: MANE), Avenzo Therapeutics.
- What is SR One Capital Management's AUM?
- SR One Capital Management manages approximately $2K in assets.